Beren Therapeutics Raises $300M in Equity and Strategic Financing to Launch Niemann-Pick Disease Therapy

Deal Summary

Beren Therapeutics secured $300 million in combined funding, including a $135 million Eisai‑backed equity round and up to $165 million of strategic financing from Hercules Capital, to support the potential U.S. launch of its infantile‑onset Niemann‑Pick disease therapy adrabetadex.